Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V938 plus pembrolizumab in advanced malignancies
NCT04135352Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 3
01
Overview
Phase 1, open-label trial of oNDV-IL12 in solid tumor, melanoma and head and neck squamous cell carcinoma (HNSCC) (9 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced Dose-Limiting Toxicity, Number of Participants Who Experienced an Adverse Event and 1 more. Started Nov 2019; status: terminated.
02
Drugs
oNDV-IL12
03
Conditions
solid tumormelanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04135352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04135352.